Antitumor action of N-(2-chloroethyl)-N-nitrosocarbamoyl derivatives of biologically active polypeptide hormone fragments. 1986

A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky

The antitumor action of the 2-chloroethylnitrosocarbamoyl derivatives of peptides related to the 9-13 amino acid residues of alpha-MSH/ACTH and of the C-terminal tetrapeptide analogue of gastrin have been investigated. Series of 2-chloroethylnitrosoureas attached to amino acids, di-, tri-, tetra-, or pentapeptides were examined in a primary screening system. Among these compounds the Pro-Val-, Lys-Pro-Val-, and Trp-Gly-Lys-Pro-Val-containing 2-chloroethylnitrosocarbamoyl groups were the most effective in the L1210 system. The human melanoma xenograft line was also affected by these agents, while colorectal xenografts were insensitive. A combination of tripeptide-2-chloroethyl-nitrosourea with BCNU induced more than additive growth inhibition of L1210 leukemia.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D009607 Nitrosourea Compounds A class of compounds in which the core molecule is R-NO, where R is UREA. Compounds, Nitrosourea
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females

Related Publications

A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky
June 1984, International journal of peptide and protein research,
A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky
December 1987, Cancer treatment reviews,
A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky
August 1988, Journal of medicinal chemistry,
A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky
March 1999, Die Pharmazie,
A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky
January 1986, Journal of cancer research and clinical oncology,
A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky
January 1984, Journal of cancer research and clinical oncology,
A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky
August 1984, Biochemical pharmacology,
A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky
June 1984, Toxicology and applied pharmacology,
A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky
August 1974, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
A Jeney, and L Kopper, and P Nagy, and K Lapis, and H Süli-Vargha, and K Medzihradszky
February 1970, Endocrinology,
Copied contents to your clipboard!